Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma

Clinical Cancer Research

Volumn 14, Issue 5, 2008, Pages 1431-1437

  Shiomi, Kazu ^a   Hagiwara, Yoshiaki ^e   Sonoue, Kouji ^a   Segawa, Tatsuya ^e   Miyashita, Kazuya ^e   Maeda, Masahiro ^e   Izumi, Hiroshi ^a   Masuda, Kimihiko ^b   Hirabayashi, Masataka ^f   Moroboshi, Takao ^g   Yoshiyama, Takashi ^c   Ishida, Atsuko ^h   Natori, Yuji ^d   Inoue, Akira ⁱ   Kobayashi, Masashi ^f   Sakao, Yukinori ^a   Miyamoto, Hideaki ^a   Takahashi, Kazuhisa ^a   Hino, Okio ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b TOKYO NATIONAL HOSPITAL   (Japan)

^c Japan Anti Tuberculosis Association   (Japan)

^d Hirano Kameido Himawari Clinic   (Japan)

^e Immuno Biological Laboratories Co Ltd   (Japan)

^f Hyogo Prefectural Tsukaguchi Hospital   (Japan)

^g YOKOSUKA KYOSAI HOSPITAL   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESOTHELIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 16K16; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ARTICLE; ASBESTOSIS; CHO CELL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ASBESTOS; ASBESTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MICE; MIDDLE AGED; PLEURAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 40949116225     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1613     Document Type: Article

References (27)

1. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, DeCamp JM. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63; discussion 63-5.
2. Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
3. Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N. Soluble mesothelin-related protein-a blood test for mesothelioma. Lung Cancer 2005;49 Suppl 1:S109-11.
4. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-53.
5. Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006;12:4225-31.
6. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin M-C. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60.
7. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-73.
8. Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, HIno O. Novel ELISA system for detection of NERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 2006;97:928-32.
9. Sugarbaker DJ, Norberto JJ, Swanson SJ. Extrapleural pneumonectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997;9:373-82.
10. Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Mentzer SJ, Lee TH. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993;11:1172-8.
11. Sugarbaker DJ, Jaklitsch MT, Bueno R, Richards W, Lukanich J, Mentzer SJ. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004;128:138-46.
12. Frebourg T, Lerebours G, Delpech B, Benhamou D, Bertrand P, Maingonnat C. Serum hyaluronate in malignant pleural mesothelioma. Cancer 1987;59:2104-7.
13. Pluygers E, Baidewyns P, Minette P, Beauduin M, Gourdin P, Robinet P. Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: rationale and practical implementations. Eur J Cancer Prev 1992;1:129-38.
14. Almudevar Bercero E, Perez GM-R, Garcia Bragado F, Jimenez C. Prognostic value of high serum levels of CA-125 inmalignant secretory peritoneal mesotheliomas affecting young women. A case report with differential diagnosis and review of the literature. Histopathology 1997;31:267-73.
15. Bonfrer JMG, Schouuwink JH, Korse CM, Baas P. Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res 1997;17:2971-3.
16. Schouwink H, Korse CM, Bonfrer JMG, Hart AAM, Bass P. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999;25:25-32.
17. Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 2001;119:1138-42.
18. Lee YC, Knox BS, Garrett JE. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions. Aust N Z J Med 1999;29:765-9.
19. Thylen A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001;92:1224-30.
20. Pettersson T, Froseth B, Riska H, Klockars M. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 1988;94:1037-9.
21. Hino O, Kobayashi E, Nishizawa M, Kubo Y, Kobayashi T, Hirayama Y. Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol 1995;121:602-5.
22. Yamashita Y, Yokohama M, Kobayashi E, Takai S, Hino O. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun 2000;275:134-40.
23. Hino O. Multistep renal carcinogenesis in the Eker (Tsc 2 gene mutant) rat model. Curr Mol Med 2004;4:807-11.
24. Nakaishi M, Kajino K, Ikesue M, Hagiwara Y, Kuwahara M, Hino O. Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin. Cancer Sci 2007;98:659-64.
25. Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int 2006;56:649-54.
26. Maeda M, Hino O. Blood tests for asbestos-related mesothelioma. Oncology 2006;71:26-31.
27. Hino O, Shiomi K, Maeda M. Diagnostic biomarker of asbestos-related mesothelioma: Example of translational research. Cancer Sci 2007;98:1147-57.